CONCENTRATIONS OF CEFPODOXIME IN PLASMA AND LUNG-TISSUE AFTER A SINGLE ORAL DOSE OF CEFPODOXIME PROXETIL

被引:14
作者
COURAUD, L
ANDREWS, JM
LECOEUR, H
SULTAN, E
LENFANT, B
机构
[1] DUDLEY RD GEN HOSP,DEPT MICROBIOL,BIRMINGHAM B18 7QH,ENGLAND
[2] ROUSSEL LABS LTD,F-75006 PARIS,FRANCE
[3] INST ROUSSEL UCLAF,F-93230 ROMAINVILLE,FRANCE
关键词
D O I
10.1093/jac/26.suppl_E.35
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Eighteen patients undergoing thoracotomy for suspected pulmonary neoplasia were given 200 mg cefpodoxime equivalent by mouth, before operation. Plasma samples were obtained before dose administration, and plasma and lung tissue samples were obtained at the time of operation which was 3, 6 or 12 h after the dose. All samples were assayed for cefpodoxime. The mean ratios for lung tissue/plasma concentrations were similar between 3 and 12 h after dose, suggesting that equilibrium between plasma and lung tissue concentrations was reached within 3 h of medication. The mean concentrations of cefpodoxime in lung tissue were 0.63±0.16, 0.52±0.09 and 0.19±0.02 mg/kg at 3, 6 and 12 h after administration, respectively. These observations indicate good, rapid and sustained penetration into lung tissue in concentrations ≥ the MIC90 for most common micro-organisms found in community-acquired pneumonia. © 1990 The British Society for Antimicrobial Chemotherapy.
引用
收藏
页码:35 / 40
页数:6
相关论文
共 6 条
[1]  
Chin N.X., Neu H.C., In vitro activity of an oral iminomethoxy aminothiazolyl cephalosporin. R–3746, Antimicrobial Agents and Chemotherapy, 32, pp. 671-677, (1988)
[2]  
Grellet J., Couraud L., Saux M.C., Roche G., Diffusion pulmonaire du cefixime chez l’homme, La Presse Medicale, 18, pp. 1589-1592, (1989)
[3]  
Imaizumi M., Kajita M., Fujita K., Niimi T., Kamiya I., Takahashi T., Et al., Clinical studies on the concentration of cefaclor in sera and lung tissues of patients with respiratory diseases, Japan Journal of Antibiotics, 39, pp. 2754-2760, (1986)
[4]  
Jones R.N., Barry A.L., Antimicrobial activity and disk diffusion susceptibility testing of U-76, 253 A (R-3746), the active metabolite of the new cephalosporin ester, U-76, 252 (CS- 807), Antimicrobial Agents and Chemotherapy, 32, pp. 443-449, (1988)
[5]  
Tremblay D., Dupront C., Ho C., Coussediere D., Lenfant B., Pharmacokinetics of cefpodoxime in young and elderly volunteers after single doses, Journal of Antimicrobial Chemotherapy, 26, pp. 21-28, (1990)
[6]  
Utsui Y., Inoue M., Mitsuhashi S., In vitro and in vivo antibacterial activities of CS– 807 a new oral cephalosporin, Antimicrobial Agents and Chemotherapy, 31, pp. 1085-1092, (1987)